trending Market Intelligence /marketintelligence/en/news-insights/trending/TMKJ7FaQvd5Q1Yqb4Rh1jg2 content esgSubNav
In This List

Las Vegas Sands to replace Nektar Therapeutics in S&P 500

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Las Vegas Sands to replace Nektar Therapeutics in S&P 500

Las Vegas Sands Corp. is joining the S&P 500, replacing San Francisco-based drugmaker Nektar Therapeutics. The change will become effective before trading opens Oct. 3.

The casino and gaming company will be added to the S&P 500 Global Industry Classification Standard Casinos & Gaming Sub-Industry Index.

Meanwhile, Nektar will replace Sotheby's in the S&P MidCap 400, also effective prior to trading Oct. 3. The company, which develops therapies for cancer, autoimmune disease and chronic pain, will be added to the S&P MidCap 400 GICS Pharmaceuticals Sub-Industry index.

Art auction house Sotheby's is being acquired by BidFair USA LLC in a $3.7 billion deal.

S&P Dow Jones Indices and S&P Global Market Intelligence are owned by S&P Global Inc.